Appoints Michael King as CFO with $450K salary and 850K share option grant

SAB Biotherapeutics, Inc.

Michael King appointed CFO effective Oct 30, 2023; Russell Beyer ceased as CFO on Oct 27.
Base salary $450,000, target annual bonus of 40% of base, and 850,000 stock options.
Options vest over 4 years: 25% on 1-year anniversary, then monthly over 36 months.
King has 25+ years in biotech research; most recently Co-Head of Healthcare at EF Hutton.
No family relationships or arrangements with others influenced his selection.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael King

Chief Financial Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2023-10-30
Filed: October 27, 2023, 7:59 PM ET

Michael King, age 62, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective October 30, 2023.

Departed

Russell P. Beyer

Chief Financial Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2023-10-27
Successor: Michael King
Filed: October 27, 2023, 7:59 PM ET

Russell P. Beyer ceased to serve as Chief Financial Officer of the Company on October 27, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael King was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Michael King, age 62, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective October 30, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Russell P. Beyer departed as Chief Financial Officer at SAB Biotherapeutics, Inc..

Action: ceased
Role: Chief Financial Officer

Exact text from the filing

Russell P. Beyer ceased to serve as Chief Financial Officer of the Company on October 27, 2023.

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-056048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.